Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05635708 · ClinicalTrials.gov registry record · Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

A Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, sponsored by BeiGene.

Active
Registry status
Phase 2
Development phase
400
Enrollment target
20
Study locations

NCT05635708: Active Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, sponsored by BeiGene.

NCT05635708 is a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 400 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05635708, a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by BeiGene.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).

Primary Outcome

ORR is defined as the percentage of participants with partial or complete response, as assessed by the investigator using the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1

Conditions Studied

Non-Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Tislelizumab
  • DRUG LBL-007
  • DRUG BGB-A445

Study Locations (20)

Other

  • Hospital de Amor Barretos - Barretos
  • Hospital Do Cancer de Londrina - Londrina
  • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus - Porto Alegre
  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto - São José do Rio Preto
  • Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira - São Paulo

New South Wales

  • Blacktown Cancer and Haematology Centre - Blacktown
  • Chris Obrien Lifehouse - Camperdown
  • Northern Beaches Hospital - Frenchs Forest
  • Port Macquarie Base Hospital - Port Macquarie

Western Australia

  • One Clinical Research - Nedlands
  • St John of God Health Care - Subiaco

California

  • Valkyrie Clinical Trials - Los Angeles

Massachusetts

  • Massachusetts General Hospital - Boston

New York

  • Memorial Sloan Kettering Cancer Center Mskcc - New York

Oregon

  • Providence Portland Medical Center - Portland

Texas

  • The University of Texas Md Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2023-03-07
Est. Completion 2026-10
Phase Phase 2
BeiGene

65 total trials

What the registry record for NCT05635708 still lists

NCT05635708 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (39% lower).

The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT05635708 names 20 study sites across 12 states, led by Other, New South Wales, Western Australia.

Frequently Asked Questions

What is clinical trial NCT05635708 about?

NCT05635708 is a clinical study titled "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer". The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung can...

What is the current status of trial NCT05635708?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2023-03-07. Estimated completion is 2026-10.

What conditions does trial NCT05635708 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer.

What interventions are being tested in trial NCT05635708?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Tislelizumab (DRUG), LBL-007 (DRUG), BGB-A445 (DRUG).

Who is sponsoring clinical trial NCT05635708?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05635708 being conducted?

This trial has 20 study locations across California, Massachusetts, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05635708's enrollment target sits among peer trials

400 98th of 454 higher than 353 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05635708, the US trial registry maintained by the National Library of Medicine. NCT05635708 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.